Search
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigational[L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion. … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).
Categories: Cellular and Gene Therapy, Preparations for Treatment of Wounds and UlcersMetacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Omidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigationalIn this group of patients, umbilical cord blood can be used as an alternative cell source since there is a lower risk of graft failure or graft-versus-host disease, even with low-grade HLA-matching. … [A258948] A pooled analysis of five prospective clinical trials found that the use of omidubicel led to stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigational[A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18. … [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard
Categories: Amino Acids, Peptides, and ProteinsBone Metastases
go.drugbank.com/conditions/DBCOND0028830Synonyms: Secondary malignant neoplasm of bone and bone marrowTabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalTabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).
Categories: Antineoplastic cell and gene therapy, Antineoplastic and Immunomodulating AgentsAnthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical
Luteinizing hormone
go.drugbank.com/drugs/DB14741ApprovedInvestigationalMixtures: MENOGON 75 IU Powder and Solvent for solution for Injection, . - Pulver und Lösungsmittel zur Herstellung einer InjektionslösungCategories: Amino Acids, Peptides, and Proteins, Hormones, Hormone Substitutes, and Hormone AntagonistsMenthyl salicylate
go.drugbank.com/drugs/DB11201ApprovedMenthyl salicylate is an ester of menthol and salicylic acid [L2808]. This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) [L2810].